Danish pharmaceutical multinational Novo Nordisk is expanding its presence in inherited blood disorder treatments ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

Thyroid disorders, common endocrine conditions, often require long-term management. Shivkumar Aggarwal, seeking lasting ...

Many doctors agree with the Food and Drug Administration’s recent decision to remove the black box warnings on at least some ...

Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...

The rare diseases treatment market is entering a pivotal phase marked by advanced therapeutic innovation, multi-stakeholder collaboration, and fundamental changes to research and ...

Following the success of the initial collection, we are pleased to present a second volume of the Research Topic, “Endocrine Insights into Heart Disease.”It ...

Giredestrant, a selective estrogen receptor antagonist and degrader given as an adjuvant therapy, shows significant ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant  given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...